Negative perception of schizophrenia is still prevalent in society. However, schizophrenia is only a mental disease that ...

The schizophrenia market size is expected to grow during the forecast period (2025–2034). DelveInsight’s analysis projects growth in the schizophrenia market, driven by rising disease prevalence, the ...

MERIT is one of several metacognitive psychotherapies, designed especially to meet the needs of individuals living with serious mental illnesses, including schizophrenia. It is deliverable in both ...

Over the next two days, her symptoms worsened, and doctors from the US decided to remove the appendix as a precaution. Appendicitis is an inflammation of the appendix, a small, tube-like organ ...

PANSS is a clinician-administered tool used to assess schizophrenia symptoms. Approved by the FDA to treat schizophrenia in September 2024, Cobenfy boasts a novel mechanism, targeting cholinergic ...

And now, nearly half of US teens say social media has a mostly negative effect on people their age — and almost the same proportion say they’re cutting back on social media use. That’s ...

The main symptoms of schizophrenia are not multiple personalities, but hallucinations, delusions, disorganised thoughts, speech and behaviour, and a difficulty in expressing emotion. A revealing ...

It is clear that schizophrenia remains one of the most complex and distressing psychiatric disorders, with a clinical picture characterized by a series of positive symptoms (hallucinations, delusions) ...

Noticeable symptoms of normal, healthy brain ageing might include a bit more forgetfulness, slower reaction time, and difficulty juggling multiple tasks. Such changes are very different from the ...

Examples include antipsychotic medication side effects like daytime sleepiness and schizophrenia symptoms like lack of motivation, fatigue, and social withdrawal. “What this means is that it’s ...

Brexpiprazole was associated with a greater reduction in schizophrenia symptoms over 6 weeks in adolescents compared with placebo, with a tolerable safety profile, in a new phase 3 trial.